299. 嚢胞性線維症 Cystic fibrosis Clinical trials / Disease details

臨床試験数 : 1,696 / 薬物数 : 1,644 - (DrugBank : 272) / 標的遺伝子数 : 96 - 標的パスウェイ数 : 170

18 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05239611 (ClinicalTrials.gov)	February 14, 2022	10/1/2022	Feasibility of Home-based Exercise Program for Adults With Cystic Fibrosis	Feasibility of Home-based Exercise Program for Adults With Cystic Fibrosis to Improve Patient-centered Outcomes, Including a Novel Measure of Ventilation	Cystic Fibrosis	Drug: Exercise	University of Kansas Medical Center	NULL	Recruiting	18 Years	N/A	All	30	Phase 2	United States
2	NCT04415268 (ClinicalTrials.gov)	June 9, 2020	28/5/2020	Combined Effect of CFTR Protein Modulator Drugs and Exercise in Cystic Fibrosis	Combined Effect of CFTR Protein Modulator Drugs and Exercise on Pulmonary Function, Fitness, Sweat Test and Quality of Life in Children With Cystic Fibrosis	Cystic Fibrosis in Children	Behavioral: Exercise;Behavioral: Unsupervised exercise;Drug: CFTR Modulators	Universidad Europea de Madrid	NULL	Recruiting	6 Years	18 Years	All	11	N/A	Spain
3	NCT04166396 (ClinicalTrials.gov)	February 17, 2020	14/11/2019	Non-pulmonary Contributors of Exercise Intolerance in Patients With Cystic Fibrosis	Non-pulmonary Contributors of Exercise Intolerance in Patients With Cystic Fibrosis	Cystic Fibrosis	Dietary Supplement: Resveratrol;Dietary Supplement: NR;Dietary Supplement: Placebo	Virginia Commonwealth University	NULL	Recruiting	18 Years	N/A	All	36	N/A	United States
4	NCT04039087 (ClinicalTrials.gov)	September 5, 2019	28/7/2019	Sildenafil Exercise: Role of PDE5 Inhibition	Mechanisms of Exercise Intolerance in Cystic Fibrosis: Role of PDE5 Inhibition	Cystic Fibrosis	Drug: Sildenafil 40mg oral capsule;Drug: Placebo Oral capsule	National Jewish Health	Augusta University;Cystic Fibrosis Foundation	Recruiting	9 Years	N/A	All	40	Phase 2/Phase 3	United States
5	NCT03965832 (ClinicalTrials.gov)	May 24, 2019	24/5/2019	HFNT During Exercise in CF	A Pilot Study to Evaluate the Feasibility of Using High-flow Nasal Therapy During Exercise in Patients With Cystic Fibrosis and Severe Lung Disease	Cystic Fibrosis	Device: HFNT during exercise;Device: Standard oxygen therapy/RA	The Leeds Teaching Hospitals NHS Trust	NULL	Recruiting	18 Years	N/A	All	20	N/A	United Kingdom
6	NCT03710538 (ClinicalTrials.gov)	April 1, 2019	20/6/2018	The Effect of a Pre-meal Snack and/or Exercise on Post-prandial Glycemic Excursions in Adults With Cystic Fibrosis	The Effect of a Pre-meal Snack and/or Exercise on Post-prandial Glycemic Excursions in Adults With Cystic Fibrosis	Cystic Fibrosis	Dietary Supplement: Snack beverage;Behavioral: Exercise	Institut de Recherches Cliniques de Montreal	NULL	Recruiting	18 Years	N/A	All	14	N/A	Canada
7	NCT03902236 (ClinicalTrials.gov)	March 1, 2019	1/4/2019	Reaction Time and Postural Control in Individuals With Cystic Fibrosis and Bronchiectasis	Evaluation of Reaction Time and Postural Control in Individuals With Cystic Fibrosis and Bronchiectasis	Cystic Fibrosis;Bronchiectasis	Other: Reaction Time and Postural Control;Other: Muscle oxygenation;Other: Exercise capacity;Other: Balance	Hacettepe University	NULL	Recruiting	6 Years	18 Years	All	60		Turkey
8	NCT03522831 (ClinicalTrials.gov)	May 1, 2018	19/3/2018	CF Bronchodilation	A Double-blind Placebo-controlled Crossover Study to Assess the Effects of Bronchodilation on Dyspnea, Ventilatory Responses, and Exercise Tolerance in Adults With Cystic Fibrosis	Lung Diseases;Cystic Fibrosis	Drug: Salbutamol;Drug: Placebo	University of British Columbia	NULL	Recruiting	19 Years	N/A	All	20	N/A	Canada
9	NCT02875366 (ClinicalTrials.gov)	September 2016	15/8/2016	A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR Mutation	A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Study of the Effect of Lumacaftor/Ivacaftor Combination Therapy on Exercise Tolerance in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation	Cystic Fibrosis	Drug: LUM/IVA;Drug: Placebo	Vertex Pharmaceuticals Incorporated	NULL	Completed	12 Years	N/A	All	70	Phase 4	Australia;United Kingdom
10	NCT02717650 (ClinicalTrials.gov)	August 25, 2016	10/3/2016	The Alfred Step Test Exercise Protocol (A-STEP), for Adults With Cystic Fibrosis.	Development; Feasibility/Safety and Validation of the Alfred Step Test Exercise Protocol (A-STEP) Developed for Adults With Cystic Fibrosis:	Cystic Fibrosis;Fibrosis;Lung Diseases;Respiratory Diseases;Genetic Diseases;Pancreatic Diseases	Other: A-STEP;Other: A-STEP (New Protocol);Other: Comparator: CPET cycle ergometer (Gold Standard)	The Alfred	Monash University	Suspended	18 Years	N/A	All	30	N/A	Australia
11	EUCTR2016-000066-34-GB (EUCTR)	24/06/2016	25/07/2017	A Study of the Effects of Lumacaftor/Ivacaftor on Exercise Tolerance in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation	A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Study of the Effect of Lumacaftor/Ivacaftor Combination Therapy on Exercise Tolerance in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation.	Cystic fibrosis in patients homozygous for the F508del-CFTR Mutation MedDRA version: 20.0;Level: PT;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]	Trade Name: Orkambi Product Name: lumacaftor /ivacaftor Product Code: VX-809/VX-770 INN or Proposed INN: lumacaftor Other descriptive name: LUMACAFTOR INN or Proposed INN: IVACAFTOR	Vertex Pharmaceuticals Incorporated	NULL	Not Recruiting			Female: yes Male: yes	66	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes	Australia;United Kingdom
12	NCT02690064 (ClinicalTrials.gov)	April 2015	19/2/2016	Mechanisms for Vascular Dysfunction and Exercise Tolerance in CF	Mechanisms for Vascular Dysfunction and Exercise Tolerance in CF	Cystic Fibrosis	Dietary Supplement: Acute Antioxidant;Dietary Supplement: Chronic Antioxidant;Other: Placebo	Augusta University	NULL	Recruiting	7 Years	N/A	All	80	N/A	United States
13	NCT02057458 (ClinicalTrials.gov)	April 2014	4/2/2014	Blood Flow and Vascular Function in Cystic Fibrosis	Role of Blood Flow and Vascular Function on Exercise Capacity in Cystic Fibrosis	Cystic Fibrosis	Drug: Sildenafil (Acute-1 hour);Drug: Sildenafil (Subchronic-4 weeks);Drug: Placebo	Augusta University	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	18 Years	N/A	All	19	Phase 2	United States
14	NCT01937325 (ClinicalTrials.gov)	February 2014	4/9/2013	CPET in CF Patients With One G551D Mutation Taking VX770	Airway Infection, Inflammatory Markers and Exercise Capacity in Patients With Cystic Fibrosis and at Least One G551D Mutation Taking VX770 (Ivacaftor)	Cystic Fibrosis	Drug: ivacaftor;Drug: placebo	The Alfred	NULL	Active, not recruiting	16 Years	70 Years	Both	20	Phase 4	Australia
15	NCT01772758 (ClinicalTrials.gov)	August 2011	16/10/2012	Cystic Fibrosis and Endothelial Function: At Rest and During Exercise	Influence of Cystic Fibrosis on Vascular Endothelial Function at Rest and During Exercise	Cystic Fibrosis	Drug: BH4 5mg;Drug: BH4 20mg;Dietary Supplement: Antioxidant Cocktail	Augusta University	NULL	Completed	7 Years	N/A	All	64	Phase 2	United States
16	NCT01759342 (ClinicalTrials.gov)	April 2008	21/12/2012	Comprehensive Exercise Training Program During Hospitalization for an Acute CF Exacerbation	The Efficacy of a Standardized Exercise Protocol in Inpatient Care of Patients With Cystic Fibrosis	Cystic Fibrosis	Behavioral: Aerobic exercise;Behavioral: Resistance exercise;Behavioral: Flexibility and postural exercise;Behavioral: Balance exercise	University of Alabama at Birmingham	NULL	Completed	6 Years	21 Years	Both	23	N/A	United States
17	NCT00434278 (ClinicalTrials.gov)	March 2007	11/2/2007	A Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease (TOPIC)	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease	Cystic Fibrosis	Drug: Dornase alfa;Drug: placebo	Genentech, Inc.	NULL	Terminated	14 Years	N/A	All	27	Phase 4	United States
18	NCT00164021 (ClinicalTrials.gov)	February 2001	13/9/2005	The Prevalence and Significance of Gastro-oesophageal Reflux in Cystic Fibrosis Before and After Lung Transplantation	The Prevalence and Significance of Gastro-oesophageal Reflux in Adults With Cystic Fibrosis Before and After Lung Transplantation, Together With the Effects of Physiotherapy Airway Clearance Techniques on Gastro-oesophageal Function	Cystic Fibrosis	Procedure: Physiotherapy, exercise, percutaneous gastrostomy feeds;Drug: Anti-reflux pharmacotherapy	Bayside Health	The Alfred;Monash University	Recruiting	16 Years	70 Years	Both	180	N/A	Australia

先頭へ